SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?


To: Bob Swift who wrote (1080)8/13/1998 8:48:00 PM
From: David Howe  Respond to of 10280
 
This news does not effect SEPR. It's a rumor 1st of all. 2nd - even if they come up with something better than prozac it won't take all of the prozac ICE market, 3rd - SEPR's prozac ICEs (there are two actually) have different markets than just depression, 4th - we are talking about around 1/20 of SEPR's pipeline.

In reality, SEPR's Prozac ICE is only a small piece of what SEPR has cooking.

Dave



To: Bob Swift who wrote (1080)8/13/1998 9:16:00 PM
From: Thomas M.  Read Replies (1) | Respond to of 10280
 
Neuropharmaceuticals require extremely lengthy and arduous testing. This is years away.

Tom